IGM Biosciences (NASDAQ:IGMS) just reported results for the fourth quarter of 2023.
- IGM Biosciences reported earnings per share of -$1.01. This was above the analyst estimate for EPS of -$1.03.
- The company reported revenue of $651,000.
- This was 7% worse than the analyst estimate for revenue of $700,000.